Treatment with IGF1R inhibitors (AG1024, PPP) and IGF1R/IR inhibitor (OSI-906) reduced the viability and induced apoptosis in CLL cells in vitro, independent of the presence of protective stromal cells, and reduced tumor burden in vivo. This evidence concerns the gene IGF1R and neoplasm.